
FDA finds lack of evidence for dry eye disease drug approval
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL states that there is “a lack of substantial evidence consisting of adequate… Read More
